How to ascertain drug safety in the context of benefit. Controversies and concerns

Lee S. Simon, C. Vibeke Strand, Maarten Boers, Peter M. Brooks, Peter S. Tugwell, Claire Bombardier, James F. Fries, David Henry, Larry Goldkind, Gordon H Guyatt, Andreas Laupacis, Larry Lynd, Tom MacDonald, Muhammad Mamdani, Andrew Moore, Ken S. Saag, Alan J. Silman, Randall Stevens, Alan Tyndall

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

There is great concern about clearly defining benefit and risk in the context of both drug development and clinical practice. In view of this pressure, the OMERACT Executive identified the need to bring together clinical trialists, pharmacoepidemiologists, clinicians, clinical epidemiologists, statistical experts, and regulatory representatives to discuss different approaches to define risk and perhaps improved ways to express it. Each attendee spoke on a given topic and the group was charged to consider the issue of risk in the context of formally posed questions. This article provides a summary of the presentations and outlines the discussions that followed. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)2114-2121
Number of pages8
JournalJournal of Rheumatology
Volume36
Issue number9
DOIs
Publication statusPublished - Sep 2009
Externally publishedYes

Fingerprint

Safety
Rheumatology
Pharmaceutical Preparations
Pressure
Epidemiologists

Cite this

Simon, L. S., Strand, C. V., Boers, M., Brooks, P. M., Tugwell, P. S., Bombardier, C., ... Tyndall, A. (2009). How to ascertain drug safety in the context of benefit. Controversies and concerns. Journal of Rheumatology, 36(9), 2114-2121. https://doi.org/10.3899/jrheum.090591
Simon, Lee S. ; Strand, C. Vibeke ; Boers, Maarten ; Brooks, Peter M. ; Tugwell, Peter S. ; Bombardier, Claire ; Fries, James F. ; Henry, David ; Goldkind, Larry ; Guyatt, Gordon H ; Laupacis, Andreas ; Lynd, Larry ; MacDonald, Tom ; Mamdani, Muhammad ; Moore, Andrew ; Saag, Ken S. ; Silman, Alan J. ; Stevens, Randall ; Tyndall, Alan. / How to ascertain drug safety in the context of benefit. Controversies and concerns. In: Journal of Rheumatology. 2009 ; Vol. 36, No. 9. pp. 2114-2121.
@article{51e32106ddc44436897a2ce43a2f649c,
title = "How to ascertain drug safety in the context of benefit. Controversies and concerns",
abstract = "There is great concern about clearly defining benefit and risk in the context of both drug development and clinical practice. In view of this pressure, the OMERACT Executive identified the need to bring together clinical trialists, pharmacoepidemiologists, clinicians, clinical epidemiologists, statistical experts, and regulatory representatives to discuss different approaches to define risk and perhaps improved ways to express it. Each attendee spoke on a given topic and the group was charged to consider the issue of risk in the context of formally posed questions. This article provides a summary of the presentations and outlines the discussions that followed. The Journal of Rheumatology",
author = "Simon, {Lee S.} and Strand, {C. Vibeke} and Maarten Boers and Brooks, {Peter M.} and Tugwell, {Peter S.} and Claire Bombardier and Fries, {James F.} and David Henry and Larry Goldkind and Guyatt, {Gordon H} and Andreas Laupacis and Larry Lynd and Tom MacDonald and Muhammad Mamdani and Andrew Moore and Saag, {Ken S.} and Silman, {Alan J.} and Randall Stevens and Alan Tyndall",
year = "2009",
month = "9",
doi = "10.3899/jrheum.090591",
language = "English",
volume = "36",
pages = "2114--2121",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "9",

}

Simon, LS, Strand, CV, Boers, M, Brooks, PM, Tugwell, PS, Bombardier, C, Fries, JF, Henry, D, Goldkind, L, Guyatt, GH, Laupacis, A, Lynd, L, MacDonald, T, Mamdani, M, Moore, A, Saag, KS, Silman, AJ, Stevens, R & Tyndall, A 2009, 'How to ascertain drug safety in the context of benefit. Controversies and concerns' Journal of Rheumatology, vol. 36, no. 9, pp. 2114-2121. https://doi.org/10.3899/jrheum.090591

How to ascertain drug safety in the context of benefit. Controversies and concerns. / Simon, Lee S.; Strand, C. Vibeke; Boers, Maarten; Brooks, Peter M.; Tugwell, Peter S.; Bombardier, Claire; Fries, James F.; Henry, David; Goldkind, Larry; Guyatt, Gordon H; Laupacis, Andreas; Lynd, Larry; MacDonald, Tom; Mamdani, Muhammad; Moore, Andrew; Saag, Ken S.; Silman, Alan J.; Stevens, Randall; Tyndall, Alan.

In: Journal of Rheumatology, Vol. 36, No. 9, 09.2009, p. 2114-2121.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - How to ascertain drug safety in the context of benefit. Controversies and concerns

AU - Simon, Lee S.

AU - Strand, C. Vibeke

AU - Boers, Maarten

AU - Brooks, Peter M.

AU - Tugwell, Peter S.

AU - Bombardier, Claire

AU - Fries, James F.

AU - Henry, David

AU - Goldkind, Larry

AU - Guyatt, Gordon H

AU - Laupacis, Andreas

AU - Lynd, Larry

AU - MacDonald, Tom

AU - Mamdani, Muhammad

AU - Moore, Andrew

AU - Saag, Ken S.

AU - Silman, Alan J.

AU - Stevens, Randall

AU - Tyndall, Alan

PY - 2009/9

Y1 - 2009/9

N2 - There is great concern about clearly defining benefit and risk in the context of both drug development and clinical practice. In view of this pressure, the OMERACT Executive identified the need to bring together clinical trialists, pharmacoepidemiologists, clinicians, clinical epidemiologists, statistical experts, and regulatory representatives to discuss different approaches to define risk and perhaps improved ways to express it. Each attendee spoke on a given topic and the group was charged to consider the issue of risk in the context of formally posed questions. This article provides a summary of the presentations and outlines the discussions that followed. The Journal of Rheumatology

AB - There is great concern about clearly defining benefit and risk in the context of both drug development and clinical practice. In view of this pressure, the OMERACT Executive identified the need to bring together clinical trialists, pharmacoepidemiologists, clinicians, clinical epidemiologists, statistical experts, and regulatory representatives to discuss different approaches to define risk and perhaps improved ways to express it. Each attendee spoke on a given topic and the group was charged to consider the issue of risk in the context of formally posed questions. This article provides a summary of the presentations and outlines the discussions that followed. The Journal of Rheumatology

UR - http://www.scopus.com/inward/record.url?scp=70349243948&partnerID=8YFLogxK

U2 - 10.3899/jrheum.090591

DO - 10.3899/jrheum.090591

M3 - Article

VL - 36

SP - 2114

EP - 2121

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 9

ER -

Simon LS, Strand CV, Boers M, Brooks PM, Tugwell PS, Bombardier C et al. How to ascertain drug safety in the context of benefit. Controversies and concerns. Journal of Rheumatology. 2009 Sep;36(9):2114-2121. https://doi.org/10.3899/jrheum.090591